Biotech News
Related news
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
SUPNSupernus2026-07-22 21:05 EST
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
ABOSAcumen Pharmaceuticals2026-09-02 20:00 EST
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
TNXPTonix Pharmaceuticals2026-08-05 11:00 EST
Tonix Pharmaceuticals to Participate in Upcoming Investor Conferences
MNOVMediciNova2026-09-08 10:00 EST
MediciNova to Participate in Two Investor Conferences in September
ANNXAnnexon, Inc.2026-09-02 12:00 EST
Annexon to Participate in Upcoming September Investor Conferences
AXSMAxsome2026-09-02 11:00 EST
Axsome Therapeutics to Participate in Upcoming Investor Conferences
ECORelectroCore2026-08-03 12:00 EST
electroCore to Participate in Upcoming Investor Conferences
ABOSAcumen Pharmaceuticals2026-09-10 20:00 EST
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026
KTTAPasithea Therapeutics2026-09-03 20:05 EST
Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
Supernus
CNS Commercial Portfolio Supernus Pharmaceuticals develops and commercializes treatments for central nervous system disorders. Its marketed portfolio spans attention-deficit hyperactivity disorder, Parkinson’s disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. Growth Products The company’s...
Recent company news
SUPNSupernus2026-09-02 20:30 EST
Supernus Pharmaceuticals to Participate in September Investor Conferences
SUPNSupernus2026-08-31 12:30 EST
Chloe Kim Teams Up with Qelbree®, the #1 Prescribed Branded Non-Stimulant ADHD Treatment*, to Help Empower People Navigating ADHD
SUPNSupernus2026-08-03 10:35 EST
Supernus Announces Second Quarter 2026 Financial Results
SUPNSupernus2026-08-03 10:30 EST
Supernus Pharmaceuticals and Indivior Pharmaceuticals to Merge, Creating a Diversified CNS Biopharmaceutical Leader with Significant Scale
SUPNSupernus2026-07-22 21:05 EST
Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026
Stock data
- Close
- 42.78 USD
- Market cap
- 2.56B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States